Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Mosonmagyaróvár

26 clinical trials in Mosonmagyaróvár, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mosonmagyaróvár at a glance
26
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

26 trials in Mosonmagyaróvár

Open in trial search

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Generate Biomedicines Inc.

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Asthma

Recruiting

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years

Asthma

Not recruiting

Study on the Effects of Lunsekimig (SAR443765) in Adults with High-Risk Asthma Not Eligible for Biologic Treatment

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol in Patients Aged 40-80 with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study of Different Doses of Amlitelimab Given by Injection Under the Skin in Adults with Moderate to Severe Asthma

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Mosonmagyaróvár

What the registry says about research in the country

01 Respiratory Medicine

Multiple innovative trials focusing on moderate to severe asthma management, testing new therapeutic approaches including lunsekimig, dupilumab, and amlitelimab. Research aims to prevent lung function decline and reduce exacerbations.

  • Asthma Exacerbation Prevention
  • Lung Function Preservation
  • Novel Treatment Evaluation

Studies particularly emphasize long-term safety and efficacy in patients with eosinophilic phenotype.

02 Pulmonary Disease Management

Clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD), evaluating new treatments like itepekimab and investigating improved delivery systems for existing medications.

  • COPD Exacerbation Reduction
  • Long-term Treatment Safety
  • Inhaler Technology Innovation

Emphasis on moderate to severe COPD patients and former smokers.

03 Cardiovascular Research

Comprehensive studies in heart failure and atrial fibrillation, testing breakthrough treatments including ponsegromab, milvexian, and vericiguat for improved patient outcomes.

  • Stroke Prevention
  • Heart Failure Management
  • Cardiovascular Event Prevention

Focus on reducing major adverse cardiovascular events and improving quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.